Lipoprotein-associated phospholipase A 2 mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: The strong heart study

Diabetes Care

Volumn 35, Issue 4, 2012, Pages 840-847

  Kizer, Jorge R ^a   Umans, Jason G ^b,c   Zhu, Jianhui ^b   Devereux, Richard B ^a   Wolfert, Robert L ^d   Lee, Elisa T ^e   Howard, Barbara V ^b,c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c DC   (United States)

^d diaDexus Inc   (United States)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LIPID; LIPOPROTEIN;

ADULT; AMERICAN INDIAN; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HEALTH STATUS; HUMAN; INCIDENCE; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; OBESITY; OUTCOME ASSESSMENT; PHENOTYPE; PREVALENCE; RISK ASSESSMENT; SEX DIFFERENCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES COMPLICATIONS; ENZYME ACTIVATION; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; MOLECULAR WEIGHT; OBESITY; POPULATION; PREVALENCE; RISK FACTORS;

EID: 84862111324     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1639     Document Type: Article

References (33)

1. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009;7(Suppl. 1):328-331
2. Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol 2009;24:358-363
3. 2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010;122:2183-2200
4. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-931 (Pubitemid 40627835)
5. Thompson A, Gao P, Orfei L, et al.; LpPLA(2) Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-1544
6. Meigs JB, Larson MG, Fox CS, Keaney JF Jr, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 2007;30:2529-2535 (Pubitemid 47547788)
7. Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990;132:1141-1155
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
10. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005;54:333-339
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470 (Pubitemid 29135798)
12. Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a populationwith a high prevalence of diabetes: the Strong Heart Study. Circulation 2005;112:1289-1295 (Pubitemid 41266723)
13. Palmieri V, Celentano A, Roman MJ, et al.; Strong Heart Study. Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. Am Heart J 2003;145:467-474 (Pubitemid 36390493)
14. Lu WQ, Resnick HE, Jablonski KA, et al. Effects of glycaemic control on cardiovascular disease in diabetic American Indians: the Strong Heart Study. Diabet Med 2004;21:311-317 (Pubitemid 38519664)
15. Wang W, Hu D, Lee ET, et al. Lipoprotein (a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study. Ann Epidemiol 2002;12:107-114
16. Hatoum IJ, Hu FB, Nelson JJ, Rimm EB. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes 2010;59:1239-1243
17. Nelson TL, Kamineni A, Psaty B, et al. Lipoprotein-associated phospholipase A (2) and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study. Diabetologia 2011;54:329-333
18. Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci USA 1989;86:2393-2397 (Pubitemid 19102515)
19. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327-338
20. Tsimihodimos V, Karabina SA, Tambaki AP, et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002;43:256-263 (Pubitemid 34184012)
21. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264-2273 (Pubitemid 41692569)
22. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-1504 (Pubitemid 38680002)
23. Constantinides A, van Pelt LJ, van Leeuwen JJ, et al. Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes. Eur J Clin Invest 2011;41:820-827
24. Kujiraoka T, Iwasaki T, Ishihara M, et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 2003;44:2006-2014 (Pubitemid 37356674)
25. Subramanian VS, Goyal J, Miwa M, et al. Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: studies with platelet-activating factor-acetyl hydrolase-deficient plasma. Biochim Biophys Acta 1999;1439:95-109 (Pubitemid 29296867)
26. Subbaiah PV, Liu M. Disparate effects of oxidation on plasma acyltransferase activities: inhibition of cholesterol esterification but stimulation of transesterification of oxidized phospholipids. Biochim Biophys Acta 1996;1301:115-126 (Pubitemid 26193069)
27. 2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med 2010;268:348-358
28. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein (a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007;27:2094-2099 (Pubitemid 350287235)
29. Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2000;20:830-835 (Pubitemid 30151700)
30. Wang W, Lee ET, Fabsitz R, Welty TK, Howard BV. Using HbA(1c) to improve efficacy of the american diabetes association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the Strong Heart Study. Diabetes Care 2002;25:1365-1370 (Pubitemid 41071147)
31. Lindsay RS, Resnick HE, Zhu J, et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005;25:e15-e16
32. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555
33. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053 (Pubitemid 38579764)